Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and efficacy profile of its active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com
Company Details
- Employees
- 33
- Founded
- -
- Address
- 111 Speen Street, Suite 306, Framingham,ma 01701,united States
- Phone
- (857) 214-7242
- jo****@****doe.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- alzheon.com
- HQ
- Framingham, MA
Alzheon, Inc. Questions
Alzheon, Inc.'s helpline number is (857) 214-7242
Alzheon, Inc.'s website is alzheon.com
Alzheon, Inc.'s LinkedIn profile is https://www.linkedin.com/company/alzheon
Alzheon, Inc. has
33 employees.
View email and phone details for 33
employees at Alzheon, Inc..
Alzheon, Inc.'s industry is
Biotechnology Research
Alzheon, Inc.'s top competitors are
Eyepoint,
Scholar Rock,
Asceneuron Sa,
Mirum Pharmaceuticals, Inc.,
Cullinan Therapeutics,
Cellectar Biosciences, Inc.,
Syros Pharmaceuticals,
Aura Biosciences,
Kura Oncology, Inc.,
Aviadobio.
Alzheon, Inc.'s support email address is john@doe.com
Alzheon, Inc.'s categories are Biotechnology Research
Alzheon, Inc.'s founding year is 2013
